Bardia Karim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bardia Karim has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Ahmad Raza Moghadamnia
1 shared publication- Ali Asadolahzadeh
Department of Internal Medicine Babol University of Medical Sciences Babol Mazandaran Iran
1 shared publication - Ali Manafi Anari
Department of Pediatrics, Ali Asghar Children Hospital, Iran University of Medical Sciences, Tehran, Iran, iums.ac.ir
1 shared publication - Amin Esmaeilnia Shirvani
School of Medicine, Babol University of Medical Sciences, Babol, Iran
1 shared publication - Arefeh Babazadeh
Infectious Diseases and Tropical Medicine Research Center, Health Research Institute Babol University of Medical Sciences Babol Iran
1 shared publication - Arina Ansari
Student Research Committee, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
1 shared publication
Latest Publications
- Open Access
- 27 December 2025
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Systematic review and meta analysis of the global incidence and clinicopathological characteristics of liver metastasis in patients with cervical cancer
Background Cervical cancer remains a major malignancy among women, with poor survival rates below 20% despite advances in care. Patients with cervical cancer are most likely to develop hematogenous metastases in the liver, followed by the lungs and bones. Although less commonly involved than other organs, the liver is associated with the poorest prognosis among metastatic sites. This study aims to estimate the global incidence of liver metastasis in cervical cancer patients and explore its clinicopathological characteristics. Methods This is a systematic review and meta-analysis conducted to assess the global incidence and clinicopathological characteristics of liver metastasis in cervical cancer patients. The review followed PRISMA guidelines, and a comprehensive search was performed in Embase, PubMed, Web of Science, Scopus, and Google Scholar up to February 28, 2025. Eligibility criteria included studies that explicitly reported the incidence of liver metastases following a diagnosis of cervical cancer, and provided data on both total cervical cancer cases and cases with liver metastases. Exclusion criteria were studies lacking clear incidence data, case reports, reviews, or studies not specific to cervical cancer. The pooled incidence was calculated using a random-effects model implemented in STATA version 17, based on raw proportions. Results were presented with 95% confidence intervals (CI), and heterogeneity was assessed using the I² statistic. Results Out of an initial 7508 articles identified across five databases, 11 studies (comprising 20 records) met the eligibility criteria and were included in the final analysis. The global pooled incidence of liver metastasis among cervical cancer patients was estimated at 1.88% (95% CI: 1.27–2.48). To explore variability among populations, we conducted subgroup analyses based on development indices. Countries with a very high Human Development Index (HDI) reported a higher incidence (2.12%, 95% CI: 1.40–2.84) than those with high (1.96%, 95% CI: 0.98–2.94) and medium (0.75%, 95% CI: 0.0–1.57) HDI levels. The incidence of liver metastasis in combination with metastases to other organs was nearly three times greater (1.76%, 95% CI: 0.99–2.53) than that of isolated liver metastasis. Furthermore, in a subgroup analysis based on histological subtype, the highest pooled incidence was observed in patients with cervical adenocarcinoma (2.36%, 95% CI: 1.35–3.37). Conclusion This meta-analysis demonstrates that while liver metastasis in cervical cancer is relatively rare, its occurrence appears more frequently in patients with advanced disease. These results underscore the need for routine liver screening in high-risk patients and support the refinement of therapeutic strategies.
- 27 December 2025
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessSystematic review and meta analysis of the global incidence and clinicopathological characteristics of liver metastasis in patients with cervical cancer
Background Cervical cancer remains a major malignancy among women, with poor survival rates below 20% despite advances in care. Patients with cervical cancer are most likely to develop hematogenous metastases in the liver, followed by the lungs and bones. Although less commonly involved than other organs, the liver is associated with the poorest prognosis among metastatic sites. This study aims to estimate the global incidence of liver metastasis in cervical cancer patients and explore its clinicopathological characteristics. Methods This is a systematic review and meta-analysis conducted to assess the global incidence and clinicopathological characteristics of liver metastasis in cervical cancer patients. The review followed PRISMA guidelines, and a comprehensive search was performed in Embase, PubMed, Web of Science, Scopus, and Google Scholar up to February 28, 2025. Eligibility criteria included studies that explicitly reported the incidence of liver metastases following a diagnosis of cervical cancer, and provided data on both total cervical cancer cases and cases with liver metastases. Exclusion criteria were studies lacking clear incidence data, case reports, reviews, or studies not specific to cervical cancer. The pooled incidence was calculated using a random-effects model implemented in STATA version 17, based on raw proportions. Results were presented with 95% confidence intervals (CI), and heterogeneity was assessed using the I² statistic. Results Out of an initial 7508 articles identified across five databases, 11 studies (comprising 20 records) met the eligibility criteria and were included in the final analysis. The global pooled incidence of liver metastasis among cervical cancer patients was estimated at 1.88% (95% CI: 1.27–2.48). To explore variability among populations, we conducted subgroup analyses based on development indices. Countries with a very high Human Development Index (HDI) reported a higher incidence (2.12%, 95% CI: 1.40–2.84) than those with high (1.96%, 95% CI: 0.98–2.94) and medium (0.75%, 95% CI: 0.0–1.57) HDI levels. The incidence of liver metastasis in combination with metastases to other organs was nearly three times greater (1.76%, 95% CI: 0.99–2.53) than that of isolated liver metastasis. Furthermore, in a subgroup analysis based on histological subtype, the highest pooled incidence was observed in patients with cervical adenocarcinoma (2.36%, 95% CI: 1.35–3.37). Conclusion This meta-analysis demonstrates that while liver metastasis in cervical cancer is relatively rare, its occurrence appears more frequently in patients with advanced disease. These results underscore the need for routine liver screening in high-risk patients and support the refinement of therapeutic strategies.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Nanotechnology
- Vol. 2025 (1)
Investigating and Comparing the Lethal Effect of Nanoempagliflozin and Metformin on the U87 Cancer Cell Line in Human Glioblastoma
Background: Although chemotherapy is highly effective in cancer treatment, it often causes numerous side effects, including drug resistance. Empagliflozin, an SGLT2 inhibitor used for diabetes, has demonstrated anticarcinogenic effects in various studies. This research examines the effects of empagliflozin nanoparticles in comparison to standard empagliflozin and metformin on the surface of U87 glioblastoma cells. Method: Nanoparticles of empagliflozin were created using chitosan–sodium alginate, and the IC50 values for empagliflozin, metformin, and the empagliflozin nanoparticles were measured. The effects of empagliflozin and metformin toxicity on the U87 cell line were studied. Following this, the flow cytometry technique was utilized to analyze its impact on apoptosis within the U87 cell line. Results: Empagliflozin nanoparticles were evaluated, showing an average size of 82.11 nm. MTT assay results indicated concentration‐dependent reductions in cell viability, with IC50 values of 12.31 μM for empagliflozin and 11.12 μM for the nanoparticles. Their combination with other drugs enhanced cell viability reduction, suggesting potential synergistic effects with chemotherapy. Flow cytometry revealed that 13.3%, 94.5%, and 97.7% of cells were in early apoptosis for the metformin, empagliflozin, and nanoparticle groups, respectively, compared to the control group, indicating distinct apoptotic patterns. Conclusion: The results of this study highlight empagliflozin nanoparticles’ promise as an independent treatment for U87 glioblastoma, attributed to their neuroprotective properties. This discovery may have a major influence on cancer treatment.
- 1 January 2025
- Published by Wiley in Journal of Nanotechnology
- Vol. 2025 (1)
Open AccessInvestigating and Comparing the Lethal Effect of Nanoempagliflozin and Metformin on the U87 Cancer Cell Line in Human Glioblastoma
Background: Although chemotherapy is highly effective in cancer treatment, it often causes numerous side effects, including drug resistance. Empagliflozin, an SGLT2 inhibitor used for diabetes, has demonstrated anticarcinogenic effects in various studies. This research examines the effects of empagliflozin nanoparticles in comparison to standard empagliflozin and metformin on the surface of U87 glioblastoma cells. Method: Nanoparticles of empagliflozin were created using chitosan–sodium alginate, and the IC50 values for empagliflozin, metformin, and the empagliflozin nanoparticles were measured. The effects of empagliflozin and metformin toxicity on the U87 cell line were studied. Following this, the flow cytometry technique was utilized to analyze its impact on apoptosis within the U87 cell line. Results: Empagliflozin nanoparticles were evaluated, showing an average size of 82.11 nm. MTT assay results indicated concentration‐dependent reductions in cell viability, with IC50 values of 12.31 μM for empagliflozin and 11.12 μM for the nanoparticles. Their combination with other drugs enhanced cell viability reduction, suggesting potential synergistic effects with chemotherapy. Flow cytometry revealed that 13.3%, 94.5%, and 97.7% of cells were in early apoptosis for the metformin, empagliflozin, and nanoparticle groups, respectively, compared to the control group, indicating distinct apoptotic patterns. Conclusion: The results of this study highlight empagliflozin nanoparticles’ promise as an independent treatment for U87 glioblastoma, attributed to their neuroprotective properties. This discovery may have a major influence on cancer treatment.
- Open Access
- 4 September 2023
- Published by Wiley in Health Science Reports
- Vol. 6 (9) , e1543
Evaluation of acceptance, attitude, and knowledge towards artificial intelligence and its application from the point of view of physicians and nurses: A provincial survey study in Iran: A cross‐sectional descriptive‐analytical study
Background and Aims: The prospect of using artificial intelligence (AI) in healthcare is bright and promising, and its use can have a significant impact on cost reduction and decrease the possibility of error and negligence among healthcare workers. This study aims to investigate the level of knowledge, attitude, and acceptance among Iranian physicians and nurses.Methods: This cross‐sectional descriptive‐analytical study was conducted in eight public university hospitals located in Tehran on 400 physicians and nurses. To conduct the study, convenient sampling was used with the help of researcher‐made questionnaires. Statistical analysis was done by SPSS 21 The mean and standard deviation and Chi‐square and Fisher's exact tests were used.Results: In this study, the level of knowledge among the research subjects was average (14.66 ± 4.53), the level of their attitude toward AI was relatively favorable (47.81 ± 6.74), and their level of acceptance of AI was average (103.19 ± 13.70). Moreover, from the participant's perspective, AI in medicine is most widely used in increasing the accuracy of diagnostic tests (86.5%), identifying drug interactions (82.75%), and helping to analyze medical tests and imaging (80%). There was a statistically significant relationship between the variable of acceptance of AI and the participant's level of education (p = 0.028), participation in an AI training course (p = 0.022), and the hospital department where they worked (p < 0.001).Conclusion: In this study, both the knowledge and the acceptance of the participants towards AI were proved to be at an average level and the attitude towards AI was relatively favorable, which is in contrast with the very rapid and inevitable expansion of AI. Although our participants were aware of the growing use of AI in medicine, they had a cautious attitude toward this.
- 4 September 2023
- Published by Wiley in Health Science Reports
- Vol. 6 (9) , e1543
Open AccessEvaluation of acceptance, attitude, and knowledge towards artificial intelligence and its application from the point of view of physicians and nurses: A provincial survey study in Iran: A cross‐sectional descriptive‐analytical study
Background and Aims: The prospect of using artificial intelligence (AI) in healthcare is bright and promising, and its use can have a significant impact on cost reduction and decrease the possibility of error and negligence among healthcare workers. This study aims to investigate the level of knowledge, attitude, and acceptance among Iranian physicians and nurses.Methods: This cross‐sectional descriptive‐analytical study was conducted in eight public university hospitals located in Tehran on 400 physicians and nurses. To conduct the study, convenient sampling was used with the help of researcher‐made questionnaires. Statistical analysis was done by SPSS 21 The mean and standard deviation and Chi‐square and Fisher's exact tests were used.Results: In this study, the level of knowledge among the research subjects was average (14.66 ± 4.53), the level of their attitude toward AI was relatively favorable (47.81 ± 6.74), and their level of acceptance of AI was average (103.19 ± 13.70). Moreover, from the participant's perspective, AI in medicine is most widely used in increasing the accuracy of diagnostic tests (86.5%), identifying drug interactions (82.75%), and helping to analyze medical tests and imaging (80%). There was a statistically significant relationship between the variable of acceptance of AI and the participant's level of education (p = 0.028), participation in an AI training course (p = 0.022), and the hospital department where they worked (p < 0.001).Conclusion: In this study, both the knowledge and the acceptance of the participants towards AI were proved to be at an average level and the attitude towards AI was relatively favorable, which is in contrast with the very rapid and inevitable expansion of AI. Although our participants were aware of the growing use of AI in medicine, they had a cautious attitude toward this.
- Open Access
- 24 February 2023
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 11 (2) , e790
Vaccination status and outcomes of COVID‐19 patients admitted to a tertiary hospital in Iran during the dominant Delta variant period
Background: This study aimed to determine the characteristics, vaccination status, and outcomes of confidence interval (COVID‐19) patients, admitted to a tertiary hospital in Iran during the predominant severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) Delta variant period.Methods: This retrospective study assessed the medical records of all hospitalized COVID‐19 patients, who were admitted to a tertiary hospital from July 10 to September 15, 2021. Adjusted binary logistic regression analyses were conducted to determine factors associated with poor outcomes.Results: More than 25% of hospitalized patients received at least one vaccine dose of SARS‐CoV‐2. The Sinopharm BIBP vaccine (China) was the most commonly received vaccine (73.3%). After adjusting for age and comorbidities, the adjusted odds ratio (AOR) for poor outcomes was significantly lower in hospitalized patients who received Remdesivir compared to those not receiving Remdesivir (AOR: 0.35; 95% confidence interval [CI]: 0.15, 0.78;p < .010). Besides, age ≥50 years (AOR: 2.51; 95% CI: 1.38, 4.59;p < .003), low educational level (AOR: 3.99; 95% CI: 1.17, 13.53;p < .027), work outside in the past year (AOR: 1.75; 95% CI: 1.02, 3.00;p < .041), and diabetes mellitus (AOR: 1.95; 95% CI: 1.66, 3.26;p = .011) were associated with more poor outcomes.Conclusion: Based on the present results, the risk of mortality and the risk of poor outcomes were lower in patients who received Remdesivir compared to those not receiving Remdesivir. The number of vaccinated patients was smaller than the unvaccinated among hospitalized patients. It is important to emphasize that vaccination reduced the need for hospitalization and that only vaccinated patients with comorbidities required hospitalization.
- 24 February 2023
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 11 (2) , e790
Open AccessVaccination status and outcomes of COVID‐19 patients admitted to a tertiary hospital in Iran during the dominant Delta variant period
Background: This study aimed to determine the characteristics, vaccination status, and outcomes of confidence interval (COVID‐19) patients, admitted to a tertiary hospital in Iran during the predominant severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) Delta variant period.Methods: This retrospective study assessed the medical records of all hospitalized COVID‐19 patients, who were admitted to a tertiary hospital from July 10 to September 15, 2021. Adjusted binary logistic regression analyses were conducted to determine factors associated with poor outcomes.Results: More than 25% of hospitalized patients received at least one vaccine dose of SARS‐CoV‐2. The Sinopharm BIBP vaccine (China) was the most commonly received vaccine (73.3%). After adjusting for age and comorbidities, the adjusted odds ratio (AOR) for poor outcomes was significantly lower in hospitalized patients who received Remdesivir compared to those not receiving Remdesivir (AOR: 0.35; 95% confidence interval [CI]: 0.15, 0.78;p < .010). Besides, age ≥50 years (AOR: 2.51; 95% CI: 1.38, 4.59;p < .003), low educational level (AOR: 3.99; 95% CI: 1.17, 13.53;p < .027), work outside in the past year (AOR: 1.75; 95% CI: 1.02, 3.00;p < .041), and diabetes mellitus (AOR: 1.95; 95% CI: 1.66, 3.26;p = .011) were associated with more poor outcomes.Conclusion: Based on the present results, the risk of mortality and the risk of poor outcomes were lower in patients who received Remdesivir compared to those not receiving Remdesivir. The number of vaccinated patients was smaller than the unvaccinated among hospitalized patients. It is important to emphasize that vaccination reduced the need for hospitalization and that only vaccinated patients with comorbidities required hospitalization.
- Open Access
- 5 May 2022
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 18 (5) , 2066425
COVID-19 vaccination challenges: A mini-review
The emergence of SARS-CoV-2 has led to the infection of many people across the globe, over six million deaths, and has placed an unprecedented burden on public health worldwide. The pandemic has led to the high-speed development and production of vaccines against the COVID-19, as vaccines can end the pandemic. At the beginning of the program, vaccinations were initially targeted only at high-risk groups, such as the elderly, those with comorbidities, or healthcare workers. Although most of the mentioned populations have received the two recommended doses, limited resources have left many authorities with an effective vaccine undersupply. Therefore, policies have been implemented to manage the available doses of the vaccines more efficiently. As there is no universally agreed consensus on this topic, we discuss the different recommendations and guidelines regarding the time interval between the two vaccine doses and explain the different scenarios for applying the two doses.
- 5 May 2022
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 18 (5) , 2066425
Open AccessCOVID-19 vaccination challenges: A mini-review
The emergence of SARS-CoV-2 has led to the infection of many people across the globe, over six million deaths, and has placed an unprecedented burden on public health worldwide. The pandemic has led to the high-speed development and production of vaccines against the COVID-19, as vaccines can end the pandemic. At the beginning of the program, vaccinations were initially targeted only at high-risk groups, such as the elderly, those with comorbidities, or healthcare workers. Although most of the mentioned populations have received the two recommended doses, limited resources have left many authorities with an effective vaccine undersupply. Therefore, policies have been implemented to manage the available doses of the vaccines more efficiently. As there is no universally agreed consensus on this topic, we discuss the different recommendations and guidelines regarding the time interval between the two vaccine doses and explain the different scenarios for applying the two doses.